Patients and transplant characteristics
| Characteristic . | Value . |
|---|---|
| No. of patients | 809 |
| Patient age | |
| Median, y (range) | 47 (19-70) |
| Older than 40 y | 543 (33) |
| 40 y or younger | 266 (67) |
| Median no. of prior chemotherapy lines (range) | 2 (0-9) |
| Donor/patient sex | |
| Female/male | 195 (24) |
| Other | 607 (75) |
| Unknown | 7 (1) |
| Diagnosis | |
| Lymphoid | 307 (38) |
| Myeloid | 424 (52) |
| Multiple myeloma | 31 (4) |
| Solid tumor | 35 (4) |
| Other | 12 (1) |
| Disease status at transplantation | |
| Not in remission | 539 (67) |
| Remission | 270 (33) |
| Donor type | |
| Mrel | 488 (60) |
| MUD | 253 (31) |
| MMrel | 68 (8) |
| Cell source | |
| PB | 425 (53) |
| BM | 384 (47) |
| Conditioning regimen | |
| Reduced intensity | 332 (41) |
| Fludarabine, Cy/+ATG/+rituximab/+alemtuzumab | 102 (13) |
| Fludarabine, melphalan (140 mg/m2)/+ATG/+alemtuzumab | 97 (12) |
| Fludarabine, busulfan/+ATG/+alemtuzumab | 50 (6) |
| Fludarabine, idarubicin/cytarabine | 31 (4) |
| Cisplatin, fludarabine, cytarabine/+ATG | 48 (6) |
| 2 CDA, cytarabine | 4 (0) |
| High-dose chemotherapy | 375 (46) |
| Busulfan, Cy/+ATG | 143 (18) |
| BEAM /+alemtuzumab/+rituximab | 59 (7) |
| Fludarabine, busulfan/+ATG | 58 (7) |
| Fludarabine, melphalan (180 mg/m2)/+ATG | 48 (6) |
| F-BAM/ FAM, ATG | 32 (4) |
| Decitabine/+busulfan, Cy | 15 (2) |
| Thiotepa/+Cy, carmustine/+melphalan, fludarabine/+ busulfan, Cy | 13 (2) |
| Cy/+ATG | 5 (1) |
| Cisplatin, fludarabine, cytarabine | 2 (0) |
| High-dose chemotherapy/TBI | 102 (13) |
| Cy/TBI | 52 (6) |
| Cy, thiotepa/TBI | 36 (4) |
| Fludarabine, melphalan/TBI | 14 (2) |
| GVHD prophylaxis | |
| Tacrolimus | 11 (1) |
| Tacrolimus/methotrexate | 759 (94) |
| Tacrolimus/methotrexate/pentostatin | 13 (2) |
| Tacrolimus/methotrexate/steroids | 3 (0) |
| Tacrolimus ± ATG ± steroids | 7 (1) |
| Cyclosporine/methotrexate | 7 (1) |
| Cyclosporine/steroids | 2 (0) |
| None | 7 (1) |
| Characteristic . | Value . |
|---|---|
| No. of patients | 809 |
| Patient age | |
| Median, y (range) | 47 (19-70) |
| Older than 40 y | 543 (33) |
| 40 y or younger | 266 (67) |
| Median no. of prior chemotherapy lines (range) | 2 (0-9) |
| Donor/patient sex | |
| Female/male | 195 (24) |
| Other | 607 (75) |
| Unknown | 7 (1) |
| Diagnosis | |
| Lymphoid | 307 (38) |
| Myeloid | 424 (52) |
| Multiple myeloma | 31 (4) |
| Solid tumor | 35 (4) |
| Other | 12 (1) |
| Disease status at transplantation | |
| Not in remission | 539 (67) |
| Remission | 270 (33) |
| Donor type | |
| Mrel | 488 (60) |
| MUD | 253 (31) |
| MMrel | 68 (8) |
| Cell source | |
| PB | 425 (53) |
| BM | 384 (47) |
| Conditioning regimen | |
| Reduced intensity | 332 (41) |
| Fludarabine, Cy/+ATG/+rituximab/+alemtuzumab | 102 (13) |
| Fludarabine, melphalan (140 mg/m2)/+ATG/+alemtuzumab | 97 (12) |
| Fludarabine, busulfan/+ATG/+alemtuzumab | 50 (6) |
| Fludarabine, idarubicin/cytarabine | 31 (4) |
| Cisplatin, fludarabine, cytarabine/+ATG | 48 (6) |
| 2 CDA, cytarabine | 4 (0) |
| High-dose chemotherapy | 375 (46) |
| Busulfan, Cy/+ATG | 143 (18) |
| BEAM /+alemtuzumab/+rituximab | 59 (7) |
| Fludarabine, busulfan/+ATG | 58 (7) |
| Fludarabine, melphalan (180 mg/m2)/+ATG | 48 (6) |
| F-BAM/ FAM, ATG | 32 (4) |
| Decitabine/+busulfan, Cy | 15 (2) |
| Thiotepa/+Cy, carmustine/+melphalan, fludarabine/+ busulfan, Cy | 13 (2) |
| Cy/+ATG | 5 (1) |
| Cisplatin, fludarabine, cytarabine | 2 (0) |
| High-dose chemotherapy/TBI | 102 (13) |
| Cy/TBI | 52 (6) |
| Cy, thiotepa/TBI | 36 (4) |
| Fludarabine, melphalan/TBI | 14 (2) |
| GVHD prophylaxis | |
| Tacrolimus | 11 (1) |
| Tacrolimus/methotrexate | 759 (94) |
| Tacrolimus/methotrexate/pentostatin | 13 (2) |
| Tacrolimus/methotrexate/steroids | 3 (0) |
| Tacrolimus ± ATG ± steroids | 7 (1) |
| Cyclosporine/methotrexate | 7 (1) |
| Cyclosporine/steroids | 2 (0) |
| None | 7 (1) |
Values indicate no. of patients (%) unless otherwise noted.
Cy indicates cyclophosphamide; CDA, chlorodeoxyadenosine; BEAM, carmustine, etoposide, cytarabine, melphalan; F-BAM, fludarabine, carmustine, cytarabine, melphalan; FAM, fluorouracil, doxorubicin, mitomycin.